Oaktree Acquisition Corp. III Life Sciences (NASDAQ:OACC) Stock Price Up 0.4% – Time to Buy?

Oaktree Acquisition Corp. III Life Sciences (NASDAQ:OACC) shares rose 0.4% during trading on Thursday . The company traded as high as $10.64 and last traded at $10.64. Approximately 353,815 shares traded hands during trading, an increase of 805% from the average daily volume of 39,109 shares. The stock had previously closed at $10.60.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Oaktree Acquisition Corp. III Life Sciences in a research report on Wednesday, October 8th. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the stock currently has a consensus rating of “Sell”.

Oaktree Acquisition Corp. III Life Sciences Price Performance

The company’s 50 day simple moving average is $10.59 and its 200 day simple moving average is $10.52.

Institutional Trading of Oaktree Acquisition Corp. III Life Sciences

A number of hedge funds have recently bought and sold shares of OACC. Alberta Investment Management Corp bought a new position in Oaktree Acquisition Corp. III Life Sciences in the 2nd quarter valued at $5,240,000. Goldman Sachs Group Inc. purchased a new position in shares of Oaktree Acquisition Corp. III Life Sciences in the 1st quarter worth about $5,417,000. DLD Asset Management LP grew its position in Oaktree Acquisition Corp. III Life Sciences by 100.0% during the first quarter. DLD Asset Management LP now owns 350,000 shares of the company’s stock valued at $3,580,000 after buying an additional 175,000 shares during the period. Meteora Capital LLC purchased a new stake in Oaktree Acquisition Corp. III Life Sciences during the second quarter worth about $517,000. Finally, JPMorgan Chase & Co. purchased a new stake in Oaktree Acquisition Corp. III Life Sciences during the second quarter worth about $2,094,000.

About Oaktree Acquisition Corp. III Life Sciences

Oaktree Acquisition Corp. III Life Sciences (NASDAQ: OACC) is a special purpose acquisition company (“SPAC”) formed to pursue merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combinations with one or more businesses in the life sciences sector. Incorporated as a Cayman Islands exempted company, OACC is sponsored by Oaktree Capital Management, a global alternative investment firm with a longstanding track record in credit strategies and private equity.